KBC Securities - MAAT PHARMA SA (MAAT) MaaT Pharma Launches capital increase for gross proceeds of € 9m #x07; #x07;

Report

KBC Securities

Mathijs Geerts Danau

MaaT Pharma Launches capital increase for gross proceeds of € 9m  

MaaT announced the launch of a capital increase through a private placement with qualified investors and retail investors. The company intends to raise € 9m, the funds will extend the runway to summer 2026 (previously February 2026). MaaT plans to use the proceeds to fund the company's development and commercialization of Xervyteg. Trading will be suspended until at least November 14 after market close. We view this raise as a positive and reiterate our BUY rating and € 17 TP.

14/11/2025 1 EN

Underlying

MAAT PHARMA SA

See profile

FR0012634822 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Mathijs Geerts Danau

Other Reports on these Companies

KBC Securities

Morning Notes : HOMI BB, HYL BB, IVA FP, NEXTA BB, RET BB, MAAT FP

: HOMI BB, HYL BB, IVA FP, NEXTA BB, RET BB, MAAT FP

5h / 9m 5h / 9m 1 EN

KBC Securities

MaaT Pharma Uneventful 3Q25 cash and revenues

MaaT reported uneventful 3Q25 cash and revenues, where its cash and cash equivalents came in at € 22.4m, providing the company with a cash runway until the end of February 2026. We note that continued growth in revenues from MaaT013's early access program (only billable in France) is a positive sign ahead of its potential EMA approval expected mid-2026. MaaT did not provide a pipeline update, though it has previously guided for results from the investigator initiated phase 2a (PICASSO) trial of MaaT013 in combination with immune checkpoint inhibitors in metastatic melanoma in 2H25, which if po...

November 4, 2025 November 4, 2025 1 EN

Hyloris Positive results for IV Aspirin, NDA will be submitted

Hyloris announced positive topline results from a pivotal study in healthy volunteers for IV aspirin. The trial achieved all its targets, enabling progression towards submission of a New Drug Application (NDA) in 2026 and expected approval in 2027. IV Aspirin is intended to be used in acute coronary syndrome and is part of Hyloris's CV portfolio, for which Hyloris needs to announce a commercial partner in the US. We model € 52m peak sales by 2037. We reiterate our HOLD and € 6 TP.

4h / 34m 4h / 34m 1 EN

Mathijs Geerts Danau

Mathijs Geerts Danau

Inventiva Raises $ 150m gross proceeds in a public offering

Inventiva announced the issuance of ~39m new ADSs in a public offering in the US at an issue price of $ 3.85 per ADS (approx. 0.9% discount to the VWAP of Euronext trading the previous day) resulting in gross proceeds of $ ~150m and net proceeds of € ~121m. Inventiva's cash runway is extended to at least 1Q27 (previously 3Q26), assuming no Tranche 3 warrants will be issued. We plan to incorporate the new share capital and cash in our target price in the future. We view this raise as a positive and reiterate our BUY rating and € 8 TP.

4h / 40m 4h / 40m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MaaT Pharma Launches capital increase for gross proceeds of € 9m &#x07; &#x07;

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : HOMI BB, HYL BB, IVA FP, NEXTA BB, RET BB, MAAT FP

MaaT Pharma Uneventful 3Q25 cash and revenues

Hyloris Positive results for IV Aspirin, NDA will be submitted

Inventiva Raises $ 150m gross proceeds in a public offering

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe

MaaT Pharma Launches capital increase for gross proceeds of € 9m